Merck's KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients with Renal Cell Carcinoma at an Increased Risk of Recurrence Following Nephrectomy
RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, for the adjuvant...
United States Nancy Kohlberg Tonik Choueiri Merck Research Laboratories Akeso Inc Asco Gu Press Program
Source: marketscreener.com